by Year
NEWS 2016
-
December 19, 2016 Corporate
-
December 05, 2016 R & D
-
November 21, 2016 Pharmaceuticals
Launch of Uptravi® Tablet for the Treatment of Pulmonary Arterial Hypertension
-
November 09, 2016 R & D
FDA Grants Fast Track Designation to NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy
-
November 08, 2016 Management & Finance PDF223 KB
-
November 08, 2016 Management & Finance
Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2016
-
October 18, 2016 Management & Finance PDF134 KB
-
September 28, 2016 Pharmaceuticals
-
September 08, 2016 Notices
-
August 08, 2016 Management & Finance
Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2016
-
June 21, 2016 R & D
-
June 02, 2016 Notices
-
May 17, 2016 R & D
-
May 12, 2016 Management & Finance
Outline of Consolidated Financial Results for the Year Ended March 31, 2016
-
May 12, 2016 Management & Finance
-
March 30, 2016 R & D
-
March 24, 2016 Corporate
Nippon Shinyaku Co., Ltd. announces final completion of API* manufacturing building
-
February 08, 2016 Management & Finance
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2015
-
February 02, 2016 R & D
Phase 1/2 Clinical Study of NS-065, a Treatment for Duchenne Muscular Dystrophy, Initiated
-
February 01, 2016 Pharmaceuticals
-
January 07, 2016 R & D
Nippon Shinyaku Submits NDA to MHLW for Selexipag for Treatment of Pulmonary Arterial Hypertension.